GERN Stock Price, Geron Corp Quote, Chart

Market Summary

USD3.73-0.07

Market Closed

-1.84%

GERN Stock Price

View Fullscreen

GERN RSI Chart

GERN Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-10.99

Price/Sales (Trailing)

4.3K

Price/Free Cashflow

-11.98

GERN Price/Sales (Trailing)

GERN Profitability

Return on Equity

-58.4%

Return on Assets

-41.78%

Free Cashflow Yield

-8.35%

GERN Fundamentals

GERN Revenue

Revenue (TTM)

520.0K

Rev. Growth (Yr)

1.3K%

Rev. Growth (Qtr)

1.2K%

GERN Earnings

Earnings (TTM)

-201.4M

Earnings Growth (Yr)

-45.3%

Earnings Growth (Qtr)

-6.57%

Breaking Down GERN Revenue

Last 30 days

2.5%

Last 90 days

80.2%

Trailing 12 Months

20.3%

How does GERN drawdown profile look like?

GERN Financial Health

Current Ratio

3.67

Debt/Equity

0.03

Debt/Cashflow

-16.37

GERN Investor Care

Shares Dilution (1Y)

16.58%

Diluted EPS (TTM)

-0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	520.0K	0	0	0
2023	494.0K	450.0K	317.0K	237.0K
2022	1.4M	1.3M	1.5M	596.0K
2021	338.0K	402.0K	403.0K	1.4M
2020	1.5M	397.0K	374.0K	253.0K
2019	3.3M	3.7M	2.8M	2.6M
2018	922.0K	1.5M	2.4M	2.5M
2017	6.0M	5.9M	968.0K	1.1M
2016	28.8M	21.3M	13.7M	6.2M
2015	1.2M	1.1M	36.3M	36.4M
2014	992.0K	1.2M	1.2M	1.2M
2013	2.2M	2.2M	1.7M	1.3M
2012	2.2M	1.9M	2.3M	2.7M
2011	4.2M	3.6M	3.3M	2.4M
2010	0	2.3M	3.0M	3.6M
2009	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Geron Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 29, 2023	aggarwal gaurav	acquired	-	-	1,970	-
Dec 29, 2023	molineaux susan	acquired	-	-	6,220	-
Dec 29, 2023	spiegel robert j.	acquired	-	-	3,406	-
Sep 29, 2023	spiegel robert j.	acquired	-	-	3,390	-
Sep 29, 2023	molineaux susan	acquired	-	-	6,191	-
Aug 24, 2023	o'farrell elizabeth g.	bought	15,064	2.28	6,607	-
Aug 24, 2023	o'farrell elizabeth g.	bought	15,000	2.28	6,579	-
Jun 30, 2023	kapur anil	acquired	15,436	2.04	7,567	evp, corp strategy & cco
Jun 30, 2023	molineaux susan	acquired	-	-	4,088	-
Jun 30, 2023	spiegel robert j.	acquired	-	-	2,239	-

Which funds bought or sold GERN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	BlackRock Inc.	reduced	-1.8	47,683,800	136,668,000	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	18.04	405,664	885,066	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	new	-	495	495	-%
May 10, 2024	WealthTrust Axiom LLC	unchanged	-	11,900	33,000	0.01%
May 10, 2024	OneDigital Investment Advisors LLC	sold off	-100	-21,100	-	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	sold off	-100	-24,849	-	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	37,036	37,036	-%
May 10, 2024	VANGUARD GROUP INC	added	4.57	38,297,400	98,568,600	-%
May 10, 2024	Covestor Ltd	reduced	-5.77	-	-	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-1.12	12,795	36,208	-%

Are Funds Buying or Selling GERN?

Are funds buying GERN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GERN

No. of Funds

Unveiling Geron Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	5.45%	29,583,449	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	55,145,502	SC 13G/A
Feb 13, 2024	vanguard group inc	5.26%	28,564,574	SC 13G
Jan 26, 2024	blackrock inc.	7.8%	42,172,679	SC 13G/A
Jan 22, 2024	state street corp	4.72%	25,625,606	SC 13G/A
Feb 14, 2023	vivo opportunity, llc	4.3%	26,901,882	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	48,423,211	SC 13G/A
Feb 03, 2023	growth equity opportunities 17, llc	-	0	SC 13D/A
Feb 01, 2023	state street corp	5.17%	19,712,189	SC 13G
Jan 31, 2023	blackrock inc.	7.2%	27,261,135	SC 13G/A

Recent SEC filings of Geron Corp

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report

Peers (Alternatives to Geron Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Geron Corp News

Latest updates

Geron Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	1221.7%	304	23.00	164	29.00	21.00	103	297	73.00	123	1,040	109	107	137	50.00	108	43.00	52.00	171	131	1,113	1,162
Operating Expenses	3.9%	56,438	54,312	47,776	51,980	40,113	42,054	40,245	28,049	28,798	32,022	25,783	28,996	28,591	23,316	20,123	16,805	16,922	30,179	16,103	15,325	11,358
S&GA Expenses	-100.0%	-	21,401	18,350	16,490	12,894	13,844	15,642	7,443	6,699	7,872	7,256	7,059	7,478	7,088	6,510	5,960	6,120	5,256	4,994	5,191	5,452
Interest Expenses	47.9%	3,433	2,321	2,066	2,003	1,922	2,005	1,817	1,581	1,479	1,135	1,058	804	743	754	6.00	-	-	-	-	-	-
Net Income	-6.6%	-55,390	-51,973	-44,805	-49,227	-38,122	-42,635	-41,051	-28,117	-30,098	-32,017	-26,697	-29,574	-27,824	-23,787	-19,651	-15,824	-16,355	-29,070	-15,180	-14,239	-10,059
Net Income Margin	50.1%	-387.30*	-776.91*	-551.38*	-380.08*	-303.49*	-238.09*	-85.64*	-86.94*	-85.85*	-83.35*	-267.70*	-250.84*	-	-	-	-	-	-	-	-	-
Free Cashflow	-53.3%	-62,868	-41,002	-51,031	-29,803	-46,737	-35,321	-29,753	-28,712	-34,024	-22,271	-22,934	-17,814	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	22.3%	482	394	413	415	425	191	233	238	198	226	229	252	259	271	286	275	143	166	164	166	176
Current Assets	32.3%	452	341	335	377	387	180	222	227	176	187	179	202	215	200	232	221	134	142	142	155	156
Cash Equivalents	171.0%	190	70.00	31.00	57.00	113	57.00	61.00	76.00	31.00	35.00	29.00	57.00	32.00	10.00	45.00	23.00	20.00	14.00	21.00	18.00	7.00
Net PPE	42.8%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
Liabilities	-100.0%	-	146	137	128	119	111	108	105	102	100	-	-	-	60.00	53.00	-	-	30.00	-	-	-
Current Liabilities	14.0%	123	108	89.00	73.00	44.00	77.00	83.00	47.00	47.00	46.00	38.00	37.00	29.00	31.00	24.00	19.00	17.00	28.00	12.00	9.00	6.00
Long Term Debt	-68.0%	11.00	35.00	30.00	41.00	51.00	30.00	38.00	45.00	50.00	50.00	35.00	34.00	24.00	24.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	35.00	30.00	41.00	51.00	30.00	38.00	45.00	50.00	50.00	35.00	34.00	24.00	24.00	-	-	-	-	-	-	-
Shareholder's Equity	39.1%	345	248	291	298	326	80.00	108	142	97.00	126	152	176	201	211	233	251	121	135	152	157	169
Retained Earnings	-3.5%	-1,653	-1,597	-1,545	-1,500	-1,451	-1,413	-1,371	-1,329	-1,301	-1,271	-1,239	-1,213	-1,183	-1,155	-1,131	-1,112	-1,096	-1,080	-1,050	-1,035	-1,021
Additional Paid-In Capital	8.3%	1,998	1,845	1,837	1,800	1,777	1,493	1,479	1,472	1,400	1,398	1,391	1,389	1,384	1,366	1,364	1,362	1,217	1,215	1,203	1,192	1,191
Shares Outstanding	10.8%	603	545	580	547	544	390	405	404	332	328	327	327	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,395	-	-	-	503	-	-	-	377	-	-	-	516	-	-	-	262	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-52.1%	-62,253	-40,938	-50,839	-29,601	-46,365	-35,181	-29,582	-28,642	-33,974	-22,168	-22,840	-17,814	-32,734	-12,614	-15,449	-12,395	-26,194	-10,366	-11,980	-8,745	-12,738
Share Based Compensation	10.4%	4,877	4,416	7,204	3,945	2,961	2,188	2,063	2,058	1,692	2,305	2,008	1,973	1,794	1,852	1,768	1,707	1,568	1,650	1,569	1,434	1,426
Cashflow From Investing	-28.1%	34,207	47,569	-4,714	-44,444	-178,733	18,988	9,842	2,810	30,427	8,365	-5,406	30,905	38,083	-21,836	13,564	-129,206	32,158	-7,013	6,037	19,412	8,964
Cashflow From Financing	344.1%	147,798	33,280	29,354	18,340	281,047	11,923	4,778	-	-	19,639	-	12,654	16,263	-581	23,976	144,265	686	10,272	8,984	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GERN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Royalties	$ 304	$ 21
Operating expenses:
Research and development	29,373	27,219
General and administrative	27,065	12,894
Total operating expenses	56,438	40,113
Loss from operations	(56,134)	(40,092)
Interest income	4,239	3,853
Interest expense	(3,433)	(1,922)
Other income and (expense), net	(62)	39
Net loss	$ (55,390)	$ (38,122)
Basic net loss per share	$ (0.09)	$ (0.07)
Diluted net loss per share	$ (0.09)	$ (0.07)
Shares used in computing basic net loss per share	603,493,451	544,459,004
Shares used in computing diluted net loss per share	603,493,451	544,459,004

GERN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 189,761	$ 70,023
Restricted cash	1,119	1,115
Marketable securities	253,288	263,676
Interest and other receivables	1,629	1,655
Prepaid and other current assets	5,712	4,879
Total current assets	451,509	341,348
Noncurrent marketable securities	20,782	43,298
Property and equipment, net	1,681	1,177
Operating leases, right-of-use assets	3,392	3,556
Deposits and other assets	4,710	4,697
Total assets	482,074	394,076
Current liabilities:
Accounts payable	9,992	6,161
Accrued compensation and benefits	6,794	13,759
Operating lease liabilities	955	949
Debt	71,526	46,893
Accrued liabilities	33,891	40,308
Total current liabilities	123,158	108,070
Noncurrent operating lease liabilities	2,829	3,006
Noncurrent debt	11,219	35,051
Commitments and contingencies
Stockholders' equity:
Common stock	591	545
Additional paid-in capital	1,997,709	1,844,988
Accumulated deficit	(1,653,159)	(1,597,769)
Accumulated other comprehensive loss	(273)	185
Total stockholders' equity	344,868	247,949
Total liabilities and stockholders' equity	$ 482,074	$ 394,076

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

CEO	Dr. John A. Scarlett M.D.
WEBSITE	geron.com
INDUSTRY	Biotechnology
EMPLOYEES	107

Geron Corp Frequently Asked Questions

What is the ticker symbol for Geron Corp? What does GERN stand for in stocks?

GERN is the stock ticker symbol of Geron Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Geron Corp (GERN)?

As of Mon May 13 2024, market cap of Geron Corp is 2.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GERN stock?

You can check GERN's fair value in chart for subscribers.

What is the fair value of GERN stock?

You can check GERN's fair value in chart for subscribers. The fair value of Geron Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Geron Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GERN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Geron Corp a good stock to buy?

The fair value guage provides a quick view whether GERN is over valued or under valued. Whether Geron Corp is cheap or expensive depends on the assumptions which impact Geron Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GERN.

What is Geron Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, GERN's PE ratio (Price to Earnings) is -10.99 and Price to Sales (PS) ratio is 4.25 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GERN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Geron Corp's stock?

In the past 10 years, Geron Corp has provided 0.077 (multiply by 100 for percentage) rate of return.